Cerity Partners LLC Takes $575,000 Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Cerity Partners LLC purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,364 shares of the company’s stock, valued at approximately $575,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. DSM Capital Partners LLC grew its stake in Neurocrine Biosciences by 15.4% in the third quarter. DSM Capital Partners LLC now owns 1,224,017 shares of the company’s stock worth $137,702,000 after purchasing an additional 163,747 shares during the period. Braidwell LP grew its stake in Neurocrine Biosciences by 3.7% in the third quarter. Braidwell LP now owns 968,024 shares of the company’s stock worth $108,903,000 after purchasing an additional 34,662 shares during the period. Jacobs Levy Equity Management Inc. grew its stake in Neurocrine Biosciences by 59.0% in the third quarter. Jacobs Levy Equity Management Inc. now owns 692,374 shares of the company’s stock worth $77,892,000 after purchasing an additional 256,920 shares during the period. Westfield Capital Management Co. LP boosted its holdings in Neurocrine Biosciences by 73.0% in the third quarter. Westfield Capital Management Co. LP now owns 649,292 shares of the company’s stock worth $73,045,000 after acquiring an additional 273,952 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Neurocrine Biosciences by 3.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 623,267 shares of the company’s stock worth $70,118,000 after acquiring an additional 18,334 shares in the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Neurocrine Biosciences news, insider David W. Boyer sold 456 shares of the company’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $141.96, for a total value of $64,733.76. Following the completion of the sale, the insider now owns 4,894 shares in the company, valued at $694,752.24. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, insider Ingrid Delaet sold 5,000 shares of the stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $145.06, for a total transaction of $725,300.00. Following the completion of the sale, the insider now owns 7,507 shares in the company, valued at $1,088,965.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David W. Boyer sold 456 shares of the stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $141.96, for a total value of $64,733.76. Following the sale, the insider now owns 4,894 shares of the company’s stock, valued at approximately $694,752.24. The disclosure for this sale can be found here. Insiders sold a total of 186,994 shares of company stock worth $25,806,409 over the last quarter. 4.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a report on Wednesday, April 10th. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a report on Tuesday. The Goldman Sachs Group boosted their target price on Neurocrine Biosciences from $134.00 to $153.00 and gave the stock a “buy” rating in a report on Thursday, January 25th. StockNews.com raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. Finally, Citigroup dropped their target price on Neurocrine Biosciences from $141.00 to $140.00 and set a “neutral” rating on the stock in a report on Thursday, February 8th. Six equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $142.38.

Neurocrine Biosciences Stock Down 0.8 %

Shares of NBIX opened at $138.97 on Thursday. The business has a 50-day simple moving average of $136.48 and a two-hundred day simple moving average of $127.62. The stock has a market cap of $13.83 billion, a price-to-earnings ratio of 57.43 and a beta of 0.25. Neurocrine Biosciences, Inc. has a 52 week low of $89.04 and a 52 week high of $148.37.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.31. The business had revenue of $515.20 million during the quarter, compared to analysts’ expectations of $518.52 million. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The business’s quarterly revenue was up 25.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.88 earnings per share. On average, equities analysts anticipate that Neurocrine Biosciences, Inc. will post 4.84 earnings per share for the current fiscal year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.